Skip to NavigationSkip to content

Biogen stock surges following patent victory over Mylan for Tecfidera

Published on 06/02/20 at 11:49am

Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a big win for the US firm.

The ruling means that Biogen maintain its exclusive rights to the drug until 2028. The Patent Trial and Appeal Board of the US Patent and Trademark Office judged that Mylan’s challenge had “not demonstrated by a preponderance of the evidence the unpatentability of claims”.

Biogen’s share value rocketed by 32% in the wake of the news. The gravity of the win can’t be overstated - Tecfidera brought in $4.43 billion last year, amounting to 30.8% of Biogen’s total revenue

While Biogen was reportedly pleased with the ruling, Mylan was unsurprisingly unhappy, with a company spokesperson noting that the firm “strongly disagrees with the decision and plans to pursue all available options for appeal.”

"Mylan continues to believe, based on the law and the facts, that Biogen’s ‘514 patent is invalid and will continue its challenges in both the district court and the Federal Circuit to remove this patent from blocking generic competition to Tecfidera," they continued.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches